12th ICTHIC SCIENTIFIC PROGRAM
Friday, May 17th 2024
10:00 -10:15 Congress Opening
10:15 - 12:30 Plenary Session 1: Emerging trends in cancer-associated thrombosis (Part I)
Chairs: Benjamin Brenner (Israel), Paolo Simioni (Italy)
Endothelial cell dysfunction in cancer: a modulator of CAT and metastasis?
Jamie O’Sullivan (Ireland)
Artificial Intelligence in CAT
Rushad Patell (USA)
The gut microbiome in cancer and thrombosis
Christoph Reinhardt (Germany)
Stroke in patients with cancer
Deborah Siegal (Canada)
Selected Abstract
OC01_IMMUNE CHECKPOINT BLOCKADE PROMOTES THROMBOSIS VIA T-CELL AND NEUTROPHIL ACTIVATION, AND TUMOR-CELL ASSOCIATED TISSUE FACTOR (TF) IN A MURINE MODEL OF COLORECTAL CANCER
Y Shim, B Sharma, Y Hisada, N Mackman, J Palumbo, M Diaz-Montero, A Khorana, Keith McCrae (USA)
OC02_NAVIGATING THE INTERPLAY OF CANCER, HEMOSTASIS, AND THROMBOSIS: INVESTIGATING TISSUE FACTOR IN COLORECTAL CANCER (CALGB/SWOG 80405)
Sandra Algaze, Y. Yang, J. Millstein, F. Battaglin, S. Soni, P. Mittal, K. Ashouri, A. Wong, P. Jayachandran, H. Arai, J. H. Lo, W. Zhang, L. Torres-gonzalez, H. Liebman, H. J. Lenz (USA)
12:30 -13:30 Debate: Do we need more complex and specific RAMs for CAT?
Chairs: Paolo Prandoni (Italy), Mario Mandalà (Italy)
YES: Andres Munoz-Martin (Spain)
NO: Ingrid Pabinger (Austria)
13:30 – 14:30 Lunch
14:30 – 15:00 Coffee
15:00 – 17:15 Plenary Session 2: Emerging trends in cancer-associated thrombosis (Part II)
Chairs: Laurent Bertoletti (France), Francesco Dentali (Italy)
Trends and Updates on the Epidemiology of Cancer-Associated Thrombosis
Ang Li (USA)
Cancer immunotherapy in CAT
Claudine Graf (Germany)
Bleeding and thrombosis during CAR-T therapy
Elena Rossi (Italy)
Location of metastasis and complications of anticoagulant treatment
Maria Barca-Hernando (Spain)
Selected Abstracts
OC03_PREDICTION OF CLINICALLY SIGNIFICANT BLEEDING IN PATIENTS ANTICOAGULATED FOR CANCER-ASSOCIATED VENOUS THROMBOEMBOLISM: VALIDATION OF THE B-CAT SCORE IN A COHORT OF PATIENTS FROM THE TESEO STUDY
Javier López Robles, M. Sánchez Cánovas, C. Iglesias, L. Ortega Morán, L. Sánchez Togneri, J. Rubio, I. Fernández Pérez, M. García De Herreros, I. García Escobar, R. Porta, E. Brozos, M. Carmona Campos, E. Martínez De Castro, H. Olivares, T. Quintanar, S. García Adrián, M. Covela Rúa, A. Carmona Bayonas, P. Jiménez Fonseca, Aj. Muñoz Martín, On Behalf of Teseo Registry Investigators (Spain)
OC04_TISSUE FACTOR PATHWAY-RELATED BIOMARKERS IN PANCREATIC CANCER: PLASMA LEVELS OF ACTIVATED FACTOR VII-ANTITHROMBIN COMPLEX MAY PREDICT VENOUS THROMBOEMBOLISM
Elena Campello, M. Spizzo, A. Castagna, F. T. M. Bosch, F. I. Mulder, N. Van Es, S. Gavasso, P. Pattini, A. Rousseau, P. Van Dreden, S. Friso, H. R. Büller, P. Simioni, N. Martinelli (Italy, The Netherlands, France)
17:15 - 17:45 Coffee Break
17:45 – 18:45 Plenary Lecture: 8th Simon Karpatkin Memorial Lecture
The Conference Chairs
Introduction to Lecture: Alok A. Khorana (USA)
VTE treatment in patients with cancer: Reflections on an evolving landscape
Agnes Y.Y. Lee (Canada)
Saturday, May 18th 2024
8:30 – 10:45 Plenary Session 3: Anticoagulation in hematological cancer patients
Chairs: Roberto Santi (Italy), Giancarlo Castaman (Italy)
VTE and mortality in patients with hematological malignancies
Kristen Sanfilippo (USA)
Management of CAT in thrombocytopenia: the uncertain balance between risks and benefits of platelet transfusion to support anticoagulation
Simon J. Stanworth (UK)
Pharmacological approach to increase platelet count: from ITP to chemotherapy-induced thrombocytopenia
Monica Carpenedo (Italy)
Selected Abstracts
OC05_THE RISK OF THROMBOEMBOLIC RECURRENCE OUTWEIGHS THE RISK OF MAJOR BLEEDING IN CANCER PATIENTS TREATED WITH TINZAPARIN, EVEN IN PATIENTS WITH FRAGILITY CRITERIA. META-ANALYSIS OF PROSPECTIVE STUDIES INVOLVING 1413 INDIVIDUAL PATIENTS’ DATA
Isabelle Mahé, C Chapelle, G. Poenou, L. Jara-palomares, A. Y. Y. Lee, O. Sanchez, G. Meyer, P. Girard, S. Laporte (France, Spain, Canada)
OC06_RAPID EXCLUSION OF CLINICALLY RELEVANT PLASMA LEVELS OF DIRECT ORAL ANTICOAGULANTS IN PATIENTS USING THE DOAC DIPSTICK IN VARIOUS INDICATIONS
Job Harenberg, W. Ageno, C. Becattini, J. Douxfils, A. Falanga, S. Hetjens, M. Marchetti, J. Vassart, F. Violi, C. Weiss, J Weitz, On Behalf of The Doac Poct Working Group (Germany, Italy, Canada)
10:45 – 11:15 Coffee break
11:15 – 13:30 Plenary Session 4: Exploring the relationship between hemostasis and cancer: New insights
Chairs: Erica De Candia (Italy), Hugo ten Cate (The Netherlands)
Platelets: A weapon against cancer
Paolo Gresele (Italy)
FXa inhibitors in cancer progression
Andrea Alimonti (Switzerland)
Coaguloma and tumor microenvironment
Janusz Rak (Canada)
Crosstalk between NETs and tumor progression
Laurence Panicot-Dubois (France)
Selected Abstracts
Selected Abstracts
OC07_INVESTIGATING A PROPOSED ANTI-CANCER IMMUNITY EFFECT OF RIVAROXABAN IN BREAST CANCER.
U. Singh, John Castle, S. Pritchard, R. Hunt, J. R. Harvey, C. Holcombe, A. Volleamere, B. Hogan, R. Vinayagam, P. G. Roy, M. Bramley, J. Kokan, C. Palmieri, K. Cox, J. Thachil, R. Jackson, A. Marshall, L. Turner, N. J. Bundred, C. C. Kirwan (UK)
OC08_TUMOR PLATELET TRANSCRIPTOME CHANGES AFFECTED BY MICRO METASTASIS
Carina Dinis Santos Rodrigues, J. Braun, S. Schubert, F. Marini, C. Graf, B. Schrörs, W. Ruf (Germany, USA)
13:30 – 14:30 Lunch sessions
14:30 – 15:00 Coffee
15:00 – 17:00 Poster Discussion Sessions
Poster Session 1: Biomarkers/Hypercoagulability I
Chair: Norma Maugeri (Italy)
Poster Session 2: Thrombohemorragic complications
Chair: TBA
Poster Session 3: Epidemiology
Chair: Marina Marchetti (Italy)
Poster Session 4: Thromboprophylaxis in cancer
Chair: Elena Rossi (Italy)
Poster Session 5: Treatment of thrombosis in cancer
Chair: Elvira Grandone (Italy)
Poster Session 6: Hemostatic proteins and cancer biology
Chair: Giulia Taraboletti (Italy)
Poster Session 7: Therapeutic challenges
Chair: Mariasanta Napolitano (Italy)
Poster Session 8: Biomarkers/Hypercoagulability II
Chair: Francesca Schieppati (Italy)
17:00 – 18:15 Interactive session: Spotlight on prevention of VTE in cancer patients
Chair: Ajay K. Kakkar (UK)
A case of thrombosis in medical patient
Walter Ageno (Italy)
A case of thrombosis in surgical patient
Giancarlo Agnelli (Italy)
A case of thrombosis during anti-cancer drug treatment
Marina Elena Cazzaniga (Italy)
Discussant: Anna Falanga (Italy)
18:15 – 19:00 Special "Noble" Session
Chairs: Anna Falanga (Italy), Caterina Rizzi (Italy)
Patient and Public Involvement in CAT Research: Necessary or glorified tokenism?
Simon Noble (UK)
Sunday, May 19th 2024
8:30 – 10:15 Plenary Session 5: Past, present, and future of CAT - A Round Table Discussion
Chairs: Elvira Grandone (Italy), Alok A. Khorana (USA)
New drugs, old problems: Immune checkpoint inhibitors and CAT
Alok A. Khorana (USA)
Real-world Outcomes Data for DOAC vs LMWH vs other Anticoagulants: Promises and Pitfalls
Nicole Kuderer (USA)
FXI inhibitors: a new option for the prevention and treatment of cancer-associated thrombosis
Marcello Di Nisio (Italy)
General Discussion
10:15 – 11.45 Plenary session 6: Novel biomarkers for predicting clinical outcomes in cancer patients
Chairs: Marina Marchetti (Italy), Andrea Remuzzi (Italy)
Proteomics prediction of CAT and mechanistic insights
Jeffrey Zwicker (USA)
Age-related clonal hemopoiesis and thrombosis
Liran I. Shlush (Israel)
Machine Learning for the prediction of CAT
Simon Mantha (USA)
Selected Abstracts
OC09_GROWTH DIFFERENTIATION FACTOR-15 IS ASSOCIATED WITH RISK OF MAJOR BLEEDING IN CANCER PATIENTS WITHOUT ANTICOAGULATION: RESULTS FROM A PROSPECTIVE COHORT STUDY
Cornelia Englisch, S. Nopp, I. Pabinger, F. Moik, D. Steiner, A. M. Starzer, M. Fritzer-szekeres, M. Preusser, A. S. Berghoff, C. Ay (Austria)
OC010_PREDICTIVE VALUE OF ACTIVATED FXI-ANTITHROMBIN COMPLEX IN CANCER ASSOCIATED THROMBOSIS (CAT): A PROSPECTIVE COHORT STUDY IN LUNG CANCER PATIENTS
Patricia Gomez-Rosas, M. Marchetti, M. Nagy, H. M. H. Spronk, L. Russo, C. Verzeroli, S. Gamba, C. J. Tartari, S. Bolognini, C. Ticozzi, F. Schieppati, R. Sarmiento, F. De Braud, G. Masci, C. Tondini, F. Petrelli, F. Giuliani, A. D'alessio, A. Santoro, G. Gasparini, R. Labianca, H. T. Cate, A. Falanga, On Behalf Of The Hypercan Investigators (Italy, The Netherlands)
11:45 - 12:45 Lunch
12:45 – 14:35 Plenary Session 7: Anticoagulation in cancer patients
Chairs: Anna Falanga (Italy), Roberto Labianca (Italy)
Risk of recurrent VTE in cancer patients after discontinuation of anticoagulant therapy
Gary E Raskob (USA)
Extended antithrombotic prophylaxis after cancer surgery
Cecilia Becattini (Italy)
Trends in the management of pediatric and adolescent patients with cancer-associated VTE
Gili Kenet (Israel)
Selected Abstracts
OC11_MANAGING A CANCER-ASSOCIATED THROMBOSIS CLINIC - OPPORTUNITIES AND CHALLENGES
Shahid Gilani, D. Chandra (United Kingdom)
OC12_PROGNOSTIC FACTORS ASSOCIATED WITH RECURRENT VENOUS THROMBOEMBOLISM IN PATIENTS WITH CANCER-ASSOCIATED VENOUS THROMBOEMBOLISM: SYSTEMATIC REVIEW AND META-ANALYSIS
F Khan, T Tritschler, Ce Marx, V Lanting, B Rochwerg, A Tran, S Fernando, D Lorenzetti, H Wunsch, J Holodinsky, K Fiest, Ht Stelfox, A Delluc, D Fergusson, G Le Gal, P Wells, N Van Es, J M Connors, Marc Carrier (Canada, USA, Switzerland, The Netherlands)
14:35 – 14:40 Concluding Remarks